Scandinavian ChemoTech AB Series B Market Cap ($8.71 Million)
Market Cap & Net Worth: Scandinavian ChemoTech AB Series B (CMOTEC-B)
Scandinavian ChemoTech AB Series B market cap. Scandinavian ChemoTech AB Series B (ST:CMOTEC-B) has a market capitalization of $8.71 Million (Skr80.93 Million) as of November 8, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #27273 globally and #589 in its home market, demonstrating a -7.36% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Scandinavian ChemoTech AB Series B's stock price Skr3.40 by its total outstanding shares 23802312 (23.80 Million). Also see CMOTEC-B operating cash flow for how efficiently the company converts equity into cash flow.
Scandinavian ChemoTech AB Series B Market Cap History (2016–2026)
Scandinavian ChemoTech AB Series B market cap history from 2016 to 2026. Data shows change from $116.69 Million to $8.71 Million (-23.64% CAGR). Check Scandinavian ChemoTech AB Series B (CMOTEC-B) share price today for real-time trading data and today's change.
Scandinavian ChemoTech AB Series B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Scandinavian ChemoTech AB Series B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore net asset growth rate of Scandinavian ChemoTech AB Series B to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.05x
Scandinavian ChemoTech AB Series B's market cap is 1.05 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $116.69 Million | $2.08 Million | -$8.14 Million | 55.99x | N/A |
| 2017 | $57.25 Million | $27.24K | -$8.33 Million | 2101.32x | N/A |
| 2018 | $28.40 Million | $560.00K | -$4.80 Million | 50.72x | N/A |
| 2019 | $29.06 Million | $556.00K | -$12.59 Million | 52.27x | N/A |
| 2020 | $34.71 Million | $131.00K | -$11.66 Million | 264.95x | N/A |
| 2021 | $43.65 Million | $49.00K | -$17.74 Million | 890.78x | N/A |
| 2022 | $12.94 Million | $473.00K | -$22.75 Million | 27.35x | N/A |
| 2023 | $6.92 Million | $2.82 Million | -$21.09 Million | 2.45x | N/A |
| 2024 | $4.59 Million | $6.57 Million | -$13.72 Million | 0.70x | N/A |
| 2025 | $12.86 Million | $12.29 Million | -$8.06 Million | 1.05x | N/A |
Competitor Companies of CMOTEC-B by Market Capitalization
Companies near Scandinavian ChemoTech AB Series B in the global market cap rankings as of November 8, 2026. Also see how large is Scandinavian ChemoTech AB Series B's balance sheet for a full breakdown of the balance sheet.
Key companies related to Scandinavian ChemoTech AB Series B by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #177 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #363 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #403 globally with a market cap of $69.36 Billion USD ( AU$98.02 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #494 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #177 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $547.09 |
| #363 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $904.35 |
| #403 | CSL Ltd | AU:CSL | $69.36 Billion | AU$202.04 |
| #494 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $254.19 |
Market Capitalization of Scandinavian ChemoTech AB Series B (2016–2026)
Market capitalization of Scandinavian ChemoTech AB Series B from 2016 to today. Between 2016 and today, Scandinavian ChemoTech AB Series B's market cap moved from $116.69 Million to $ 8.71 Million, with a yearly change of -23.64%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr8.71 Million | -32.27% |
| 2025 | Skr12.86 Million | +180.45% |
| 2024 | Skr4.59 Million | -33.70% |
| 2023 | Skr6.92 Million | -46.53% |
| 2022 | Skr12.94 Million | -70.36% |
| 2021 | Skr43.65 Million | +25.76% |
| 2020 | Skr34.71 Million | +19.42% |
| 2019 | Skr29.06 Million | +2.32% |
| 2018 | Skr28.40 Million | -50.38% |
| 2017 | Skr57.25 Million | -50.94% |
| 2016 | Skr116.69 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 7th, 2026 the market cap of Scandinavian ChemoTech AB Series B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $8.71 Million USD |
| MoneyControl | $8.71 Million USD |
| MarketWatch | $8.71 Million USD |
| marketcap.company | $8.71 Million USD |
| Reuters | $8.71 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Scandinavian ChemoTech AB Series B
Neem's Hill AB, a medical technology company, engages in the development of patented treatment alternatives for humans and animals with cancer in Sweden and internationally. It offers IQwave, an electroporation that generates tumor-specific electrical stimulation for the treatment of solid superficial tumors of various sizes and locations. Neem's Hill AB was formerly known as Scandinavian ChemoTe… Read more